U.S. Online Retail and Ecommerce Stock News

ReNew Energy Global (RNW) has drawn attention after recent share price moves left the stock with mixed return patterns, including a gain over the past month but declines across the past 3 months and year. See our latest analysis for ReNew Energy Global. The recent 4.05% 1 month share price return contrasts with a 29.60% 3 month share price decline and a 19.76% 1 year total shareholder return loss, suggesting momentum has picked up in the short term after a weaker longer run. If ReNew’s swings...

Energy Vault Holdings, Inc. previously filed a shelf registration for US$180.55 million of common stock, while also beginning construction on the 150 MW/300 MWh SOSA Energy Center battery storage project in Madison County, Texas under its Asset Vault "Own & Operate" platform. This combination of fresh financing capacity and the company’s first Asset Vault project in the ERCOT North market highlights a shift toward owned infrastructure backed by recurring revenues and supported by a US$300...

Recently, BrightSpring Health Services attracted heightened investor attention as analysts highlighted its position in home and community-based healthcare, particularly serving Medicare, Medicaid, and insured populations through its Pharmacy Solutions and Provider Services segments. An interesting angle is how this analyst enthusiasm centers on BrightSpring’s growth prospects in integrated home-based care, a part of healthcare that is gaining importance as care increasingly shifts away from...

Why DiamondRock Hospitality Stock Is Back on Investor Radars DiamondRock Hospitality (DRH) is drawing fresh attention after Deutsche Bank upgraded the stock, along with a 12.5% dividend increase for 2025 and a planned move to Nasdaq's Global Select Market. See our latest analysis for DiamondRock Hospitality. The stock has been quietly gathering momentum, with a 20.31% 90 day share price return and a 1 year total shareholder return of 8.07%. This suggests sentiment has improved alongside the...

Why Sarepta’s recent safety and revenue setbacks matter for SRPT Sarepta Therapeutics (SRPT) has been under pressure after missing 2025 net product revenue forecasts and facing serious safety and regulatory issues tied to its Elevidys gene therapy, including FDA warnings and reported patient deaths. See our latest analysis for Sarepta Therapeutics. Those safety and revenue setbacks have fed into weak momentum, with a 1-day share price return of 6.54% and a 7-day return of 7.95%, while the...

If you are wondering whether Mastercard's share price still makes sense at current levels, the key question is how its underlying value compares with what the market is paying. The stock recently closed at US$542.65, with returns of a 6.5% decline over 7 days, a 4.1% decline over 30 days, a 3.6% decline year to date, 4.3% over 1 year, 50.1% over 3 years, and 67.0% over 5 years. This gives you a mix of shorter term weakness and longer term strength to consider. Recent headlines around...

If you are wondering whether Illumina's current share price reflects its true worth, this article walks through the key numbers that matter before you make up your mind. Illumina's stock recently closed at US$145.30, with returns of 10.4% over 30 days, 8.2% year to date and 5.8% over 1 year, but declines of 23.9% over 3 years and 63.1% over 5 years, highlighting how mixed the journey has been for long term holders. Recent news around Illumina has focused on ongoing questions about its...

If you are wondering whether Pfizer's current share price fairly reflects its fundamentals, you are not alone. This article is designed to help you weigh that up clearly. Pfizer shares last closed at US$25.89, with returns of 2.4% over the past 7 days, 1.4% over 30 days, 2.8% year to date, 4.8% over 1 year, a 31.5% decline over 3 years, and a 9.4% decline over 5 years. This provides important context before looking at any valuation numbers. Recent headlines around Pfizer have focused on the...

In early January 2026, Acadia Pharmaceuticals used the J.P. Morgan Healthcare Conference and Biotech Showcase to outline its long-range plans, including projected combined net sales of about US$1.70 billion by 2028 from NUPLAZID and DAYBUE and the staged U.S. launch of DAYBUE STIX for Rett syndrome starting in Q1 2026. The company also highlighted an upcoming Phase 2 readout for remlifanserin in Alzheimer’s disease psychosis expected between August and October 2026, underlining management’s...

Agilysys, Inc. recently announced that YMCA of the Rockies has adopted 15 of its hospitality software solutions to modernize lodging, dining, activities and guest services across its two large Colorado campuses, Estes Park Center and Snow Mountain Ranch. This wide-ranging, integrated deployment at one of the largest family and group resorts in the United States underscores Agilysys’s ability to support complex, high-capacity hospitality operations with a single software ecosystem. We’ll now...

With no single event driving headlines today, Amkor Technology (AMKR) is drawing attention as investors weigh its recent share performance, current valuation signals and the scale of its outsourced semiconductor packaging and test operations. See our latest analysis for Amkor Technology. Recent trading has been choppy, with a 1-day share price return of 1.09% and a 7-day share price return showing a 3.53% decline. This comes alongside a much stronger 30-day and 90-day share price return of...

Regions Financial recently announced that longtime Chief Financial Officer and Senior Executive Vice President David J. Turner, Jr. will retire on March 31, 2026, with current Controller and head of Corporate Finance Anil D. Chadha set to assume the CFO and Senior Executive Vice President roles. This carefully planned internal succession, featuring a finance leader deeply involved in Regions’ reporting, capital, and risk analytics functions, is important because it signals continuity in how...

Why Sterling Infrastructure Is On Investors’ Radar Sterling Infrastructure (STRL) has been drawing attention after strong multi year total returns, with 1 year and 3 year figures well above its shorter term moves over the past month and past 3 months. See our latest analysis for Sterling Infrastructure. The recent 1 day share price return of 5.34% and 7 day share price return of 13.00% at a share price of $336.31 come after a softer 90 day share price return of a 5.42% decline. However, the...

If you are wondering whether General Electric's share price still offers value after a big run in recent years, you are not alone. The stock last closed at US$319.94, with returns of 1.7% over 7 days, 7.1% over 30 days, a small 0.3% decline year to date, and 79.0% over 1 year, while the 3 year return is very large and the 5 year return is close to 5x. Recent attention on General Electric has centered on its ongoing transformation into a more focused industrial group and continuing portfolio...

If you are wondering whether Merck’s current share price lines up with its underlying value, you are not alone. This article is built to help you frame that question clearly. Merck’s stock recently closed at US$110.97, with returns of 12.9% over the last 30 days and 14.3% over the last year, following a 68.0% return across the past 5 years. Over recent months, investors have been reacting to ongoing product developments and the broader outlook for large pharmaceutical names. This has helped...

Earlier this month, CRISPR Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference and highlighted progress across its gene-editing portfolio, including CASGEVY, CTX310, CTX320, CTX611, and its CAR-T program zugocabtagene geleucel. The company’s broad pipeline across cardiovascular, autoimmune, oncology, and rare diseases, combined with expanded collaborations such as its work with Eli Lilly, underscores how gene editing is moving from concept toward a diversified...

In January 2026, Oruka Therapeutics reported positive interim Phase 1 data for ORKA-002, showing a 75–80 day half-life, sustained IL-17 inhibition, and a safety profile in healthy volunteers that was consistent with other anti-IL-17 therapies, while outlining Phase 2 plans in psoriasis and hidradenitis suppurativa. The extended half-life and twice-yearly dosing potential for ORKA-002, together with yearly dosing being explored for ORKA-001, positions Oruka around less frequent biologic...

If you are wondering whether Parker-Hannifin's current share price really reflects its underlying worth, you are not alone. The stock recently closed at US$944.58, with returns of 4.2% over 7 days, 8.0% over 30 days, 5.7% year to date, 44.8% over 1 year and 228.9% over 3 years. This naturally raises questions about how much of this performance is already priced in. Recent coverage around Parker-Hannifin has focused on its position as a major player in motion and control technologies and its...

Vontier Corporation was recently named to CDP’s 2025 “A List” for Climate Change, received a “B” for Water Security, and appointed former COO Shiri Levi-Laor as CEO of its EV-charging software subsidiary Driivz. These developments highlight Vontier’s focus on sustainability credentials and leadership in EV infrastructure software, reinforcing its role in the multi-energy transition. We’ll now examine how Vontier’s CDP climate leadership recognition could influence its existing investment...

Norwegian Cruise Line Holdings (NCLH) is back in focus after its latest financial figures highlighted annual revenue of US$9.7b and net income of US$663.5m. This invites a closer look at how the stock reflects this performance. See our latest analysis for Norwegian Cruise Line Holdings. At a share price of US$22.87, Norwegian Cruise Line Holdings has seen a 6.17% 1 month share price return. Its 1 year total shareholder return shows a 13.5% decline, which contrasts with a 54.74% gain over...

Calavo Growers (CVGW) just wrapped up FY 2025 with Q4 revenue of US$124.7 million and basic EPS of US$0.21. Trailing 12 month revenue came in at US$648.4 million and EPS at US$1.11, supported by a trailing net profit margin of 3.1% versus 1.0% in the prior year. Over the last few quarters, revenue has ranged from US$154.4 million to US$190.5 million with quarterly EPS between US$0.21 and US$0.38. This points to a picture of improving profitability that puts margins, rather than top line...

In recent days, a US Senate Judiciary Committee report alleged that UnitedHealth Group used aggressive tactics, including AI tools and in‑home visits, to secure payment‑boosting diagnoses under Medicare Advantage, prompting multiple civil and criminal investigations. At the same time, UnitedHealth has released independent actuarial studies arguing that Medicare Advantage lowers government and patient costs, underscoring a sharp contrast between policymakers’ concerns over billing practices...

If you are wondering whether Amgen’s current share price gives you good value for your money, you are in the right place. This article is built to help you connect the dots between the share price and what you are actually paying for. Amgen’s stock closed at US$330.03 recently, with a 0.7% year-to-date return and a 26.5% return over the last year. This has likely caught the eye of investors watching how the risk and reward balance is evolving. Recent news flow around Amgen has focused on its...

What Wendy's new Biggie Deals launch could mean for the stock Wendy's (WEN) has rolled out a refreshed Biggie Deals menu with $4, $6, and $8 options, tying this value push directly to its Project Fresh plan to lift guest experience and profitability. See our latest analysis for Wendy's. At a share price of $8.53, Wendy's has seen a 1-day share price return of 0.59% and a 30-day share price return of 2.16%. Its 1-year total shareholder return of 39.09% and 3-year total shareholder return of...